A new weight-loss strategy being studied at the University of California, Berkeley, could help the body burn more fat while preserving muscle, potentially addressing one of the biggest limitations of current obesity treatments. Researchers have identified a compound that increases the body’s energy expenditure rather than simply reducing food intake.
In experiments with mice, the compound improved blood sugar regulation, lowered harmful blood fats, and helped obese animals lose fat without a significant decline in lean muscle mass. It also increased energy expenditure by as much as 18%, even though the mice did not become more physically active or show an increase in body temperature.
The findings, published in Science Advances, suggest a promising new direction for treating obesity, diabetes, and fatty liver disease. The experimental compound also appeared to enhance the benefits of widely used weight-loss medications such as Ozempic and Wegovy when administered together. However, its safety and effectiveness have not yet been established in humans.
A Different Approach to Weight Loss Than Ozempic
Over the past five years, GLP-1 drugs have transformed the treatment of obesity and related metabolic conditions, including diabetes and fatty liver disease. Medications such as Ozempic, Wegovy, Mounjaro, and Zepbound have helped many patients achieve substantial weight loss while also improving blood sugar control.
Despite these advances, the drugs have important limitations. Nausea and other digestive side effects can make treatment difficult for some patients. Because these medications reduce appetite and food intake, they may also increase the risk of poor nutrition and muscle loss. Over time, excessive muscle loss can contribute to weakness, frailty, and other health problems.
The Berkeley researchers set out to explore a fundamentally different strategy. Instead of focusing only on reducing calorie intake, they investigated whether it might be possible to increase the amount of energy the body burns.
This process, known as energy expenditure, includes the calories used to maintain basic bodily functions, regulate metabolism, and support daily activity. Increasing energy expenditure could potentially help people lose weight without depending entirely on eating less.
“Body weight responds to two levers: taking in fewer calories or spending more energy,” said Anders Näär, a professor of metabolic biology and nutrition at UC Berkeley and senior author of the study. “GLP-1s work almost entirely on the first, so we went after the second.”
A Compound That Burns Fat While Preserving Muscle
The researchers focused on a molecule called 5-tetradecyloxy-2-furoic acid, or TOFA, which has an unusual combination of effects on metabolism.
TOFA interferes with the production of lipids, a broad group of fatty substances that includes cholesterol and triglycerides. These molecules play essential roles in the body, but excessive levels of certain lipids can contribute to metabolic disorders and cardiovascular disease.
At the same time, TOFA activates genes involved in taking up and burning fat for energy. This dual effect allows the compound to influence both how the body produces fat and how it uses fat as fuel.
In mice, TOFA treatment produced several encouraging results. The animals became more sensitive to insulin, the hormone that helps move glucose from the bloodstream into cells. Improved insulin sensitivity makes it easier for the body to control blood sugar, an important benefit for people with diabetes or insulin resistance.
The compound also lowered triglyceride levels and improved features of fatty liver disease, a condition in which excess fat builds up in liver cells and can eventually impair liver function.
Perhaps most notably, obese mice treated with TOFA lost weight primarily through reductions in body fat without experiencing significant losses of lean muscle mass. This distinction could be especially important because maintaining muscle is critical for strength, mobility, and long-term metabolic health.
How TOFA Increases Energy Burning by 18%
Although TOFA was first identified in the 1970s, the new research revealed additional properties that may make it especially useful for treating metabolic disease.
The compound belongs to a class of substances known as ACC inhibitors, which interfere with enzymes that help the body manufacture fatty acids, effectively slowing the production of certain fats.
Other ACC inhibitors have previously reached mid-stage clinical trials, but none has been approved for metabolic diseases. One major challenge has been an unexpected side effect: many of these compounds raise triglyceride levels in the blood, potentially increasing the risk of cardiovascular problems.
The Berkeley team found that TOFA does more than inhibit ACC. It also activates two cellular receptors called PPARα and PPARδ, which help regulate the genes responsible for fat metabolism.
These receptors act like molecular switches. When activated, they trigger processes that allow cells to absorb fatty acids and break them down to produce energy. In effect, TOFA simultaneously reduces the production of certain fats and encourages the body to burn fat that is already available.
In mice, this activity increased energy expenditure by as much as 18%, without requiring additional physical activity or raising body temperature. Unlike other ACC inhibitors, TOFA also did not cause triglyceride levels to rise, possibly because of its additional effects on fat metabolism.
“TOFA appears to engage a coordinated metabolic response,” said study first author Justin Y. Lee, a postdoctoral student at UCSF who conducted the research as a Ph.D. student at Berkeley. “It is not simply blocking lipid synthesis. It is also activating energy expenditure pathways that may help the body handle excess lipid and glucose more effectively.”
To test whether these effects could be reproduced with separate treatments, the scientists gave mice a combination of two different compounds. One blocked lipid production, while the other stimulated energy expenditure.
Surprisingly, this two-compound approach was less effective than TOFA alone at improving overall metabolic health. The finding suggests that TOFA’s ability to influence multiple metabolic processes through a single molecule may be a key part of its effectiveness.
Could TOFA Make Ozempic and Wegovy More Effective?
The researchers also investigated whether TOFA could improve the outcomes of existing GLP-1 medications.
They tested the compound alongside semaglutide, the active ingredient in Ozempic and Wegovy, as well as tirzepatide, which is sold as Mounjaro and Zepbound.
These medications primarily help people lose weight by reducing appetite and food intake. TOFA, by contrast, targets the other side of the energy balance equation by increasing how much energy the body expends.
When the researchers combined TOFA with these medications in mice, the results were more favorable than those produced by either treatment alone. The combinations led to greater improvements in body weight, blood glucose regulation, insulin levels, and triglycerides.
This suggests that treatments targeting calorie intake and energy expenditure could potentially work together to produce stronger metabolic benefits.
“In our combination experiments, TOFA worked additively or synergistically with the GLP-1 appetite-suppressing drugs, so we view it as complementary rather than as a replacement,” Näär said.
In other words, the researchers do not necessarily see TOFA replacing medications such as Ozempic or Wegovy. Instead, it could eventually become an additional treatment that helps address obesity and related metabolic conditions through a different biological mechanism.
A Promising Discovery, but Human Trials Are Still Needed
Despite the encouraging results, the researchers emphasize that TOFA remains an experimental compound. All of the findings so far come from animal studies, and scientists have not yet determined whether it is safe or effective in humans.
Further research will be needed to determine whether the same metabolic improvements can be achieved in people and whether the treatment could offer meaningful advantages over existing medications.
To help advance the research toward potential clinical applications, the Berkeley scientists have launched a biotechnology company called ReRx Therapeutics. The effort has received support from the university’s life sciences entrepreneurship network, including Nucleate and Berkeley SkyDeck.
If the findings eventually translate to humans, TOFA could become an important addition to the growing range of treatments for obesity and diabetes. By encouraging the body to use more energy while helping preserve muscle, the compound points toward a potentially different path to healthier weight loss.
Also Read
- Potential Blood Test Could Detect CTE in Living Patients
- Merck Partners with Isomorphic Labs to Accelerate Drug Discovery for Key Oncology Target
- Pediatric Imaging Associated with Dose-Dependent Brain Tumor Risk in Children and Adolescents
- Trump Administration Accused of Rolling Back Cancer Protections, Report Finds


